<DOC>
	<DOCNO>NCT02166762</DOCNO>
	<brief_summary>This prospective clinical trial determine optimal QLV interval implantation achieve best possible response cardiac resynchronization therapy heart failure patient .</brief_summary>
	<brief_title>Correlating QLV Interval Left Ventricular ( LV ) Lead Position Patients Receiving Cardiac Resynchronization Therapy .</brief_title>
	<detailed_description>Heart failure grow epidemic United States . Heart failure associate shortness breath , reduce exercise tolerance , manifestation peripheral fluid retention . As disease progress , development cardiac dyssynchrony ( failure heart act one unit ) electrical mechanical function myocardium . During implantation cardiac resynchronization therapy defibrillator ( CRT-D ) device , three electrical wire place right atrium ( RA ) , right ventricle ( RV ) coronary venous system drain blood leave ventricle ( LV ) . The LV lead place posterolateral tributary coronary venous system use special delivery tool . Pacing therapy resynchronize heart show improve functional class mortality patient severe heart failure i.e . New York Heart Association ( NYHA ) class III IV functional status . Current indication cardiac resynchronization therapy ( CRT-D ) include severe cardiomyopathy ( Ejection Fraction &lt; 35 % ) , shortness breath rest minimal exertion ( NYHA class II , IV ) , prolong QRS &gt; 130ms surface echocardiogram ( ECG ) life expectancy one year . CRT-D therapy result decrease heart failure admission improvement quality life . Response CRT associate improvement functional status one NYHA functional class schema evidence reverse remodeling ( decrease end systolic LV dimension 15 % ) . However across clinical trial , third patient non-responders CRT therapy . Non-ischemic etiology heart failure presence electrical dyssynchrony surface ECG suggest QRS &gt; 150ms associate good response CRT . Non response CRT due inappropriate patient selection , inappropriate device programming , inappropriate lead placement . However , inappropriate lead placement factor change device implantation . Adverse change morality heart failure occur sub-optimal position LV lead . Most echocardiographic parameter predict responder clinically useful . Appropriate positioning near area heart late activation ( usually posterolateral segment leave ventricle ) associate good response . Inter-ventricular delay measure time delay two lead leave right ventricle ( RV-LV delay ) show well predictor response . Interval first deflection surface ECG bipolar electrogram ( QLV interval ) use surrogate identify delay segment leave ventricle . Preliminary study show well response use approach lead placement region late activation . SMART AV study use similar algorithm assessing delay also show trend well response use QLV interval . However , fluoroscopic lead position correlate QLV interval study . We plan measure area delay activation target effective lead placement map coronary vein target long QLV interval patient . For study , medical history demographic information collect patient well clinical information procedure . The QLV measurement collect prior implant LV lead . The QLV interval define measurement onset QRS width surface ECG first large positive negative peak LV electrogram ( EGM ) cardiac cycle . QLV EGM take either LV pace lead and/or .014 wire . QLV EGM 's measure three distinct point ( basal , mid , distal ) within target vessel . Each data point average four six beat allow respiratory variance , record use Bard mapping system . The final lead position area vein long QLV interval appropriate sense pace threshold . The QLV measurement conduct , addition standard care procedures CRT-D implantation patient enrol clinical trial .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Arrhythmias , Cardiac</mesh_term>
	<criteria>Patients indicate CRTD device accord current guideline implantation cardiac pacemaker antiarrhythmia device Patients age 18 Patients pregnant Patients intravenous contrast due allergic reaction chronic renal insufficiency Patients unable unwilling reason consent study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Cardiac Resynchronization Therapy</keyword>
	<keyword>Biventricular implantable cardioverter defibrillator</keyword>
	<keyword>Heart failure</keyword>
	<keyword>Cardiomyopathy</keyword>
	<keyword>QLV</keyword>
	<keyword>LV lead placement</keyword>
	<keyword>Arrhythmia</keyword>
</DOC>